Background

lung cancer, tumor
LUNG CANCER, PROLIFERATION, TUMOR
According to GLOBOCAN 2020, lung cancer incidence and mortality rate are far ahead worldwide [Iruplinalkib (WX-0593) is a novel and highly selective ALK/c-ros oncogene 1 (ROS1) TKI, which was developed by Qilu Pharmaceutical Co., Ltd., Jinan, China. The results of preclinical studies showed that it could effectively inhibit proliferation of crizotinib-sensitive or -resistant tumor cell lines, and Here we reported the single-arm, phase II study (INTELLECT) results of the efficacy and safety of iruplinalkib for 